Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1421-1440 of 2,251 trials

Heart Attack Recovery: Bempedoic Acid Study

We are investigating whether adding bempedoic acid to standard cholesterol medications helps heart attack patients reach their cholesterol goals. This study aims to improve treatment for those not meeting guidelines with current therapies.

Heart Attack1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Immunotherapy for Advanced Cancer: Standard vs. Reduced Dose

We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.

Advanced or Metastatic Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: Dapagliflozin Treatment Study

We are investigating if dapagliflozin can help prevent the return of atrial fibrillation after cardioversion compared to usual care. This study aims to see how well it works in prolonging the time before atrial fibrillation recurs.

Atrial Fibrillation≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Esophageal Cancer: Trastuzumab and Pertuzumab Study

We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.

HER2 Positive Esophageal Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Acute Myocarditis: Ibuprofen vs. Standard Pain Relief

We are studying whether ibuprofen can better improve heart health compared to regular pain relief in patients with acute myocarditis. This trial focuses on how these treatments affect heart imaging results after six months.

Acute Myocarditis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Kidney Transplant Rejection: Everolimus Study

We are studying whether everolimus can help kidney transplant patients with a specific type of rejection maintain kidney function and reduce damage. This trial looks at its effects over six months.

Kidney Failure6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesNephrology

Leiomyosarcoma: Trabectedin vs. Gemcitabine

We are comparing two treatments, Trabectedin and Gemcitabine, for patients with advanced leiomyosarcoma who have already received chemotherapy. The goal is to see which treatment works better in slowing down cancer growth and improving survival.

Leiomyosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colorectal Cancer: Amivantamab with Chemotherapy

We are comparing a new treatment combining Amivantamab and chemotherapy to Cetuximab with chemotherapy for patients with certain types of colorectal cancer. This study aims to find out which option may help patients live longer without their cancer worsening.

Left-sided Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Achondroplasia: Long-Term Study of Infigratinib

We are studying the long-term safety and effects of Infigratinib in children with Achondroplasia. The goal is to see how it impacts their growth and overall health.

Achondroplasia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology